Hong Kong, July 28, 2025 — RWA Group Limited, a wholly-owned subsidiary of Hong Kong International New Economic Research Institute Ltd. (INERI), today announced that it is in advanced discussions with Shanghai Huikai Medical Technology Co., Ltd. (“Huikai Medical”) to launch a strategic partnership focused on tokenizing medical devices as real-world assets (RWA).The collaboration aims to pioneer blockchain-enabled medical asset financing and lifecycle management.

Founded in December 2018, Huikai Medical is a leading innovator in minimally invasive urological medical devices, integrating expertise across R&D, clinical practice, and sales. The company was co-founded by senior engineers with deep industry experience, urology professors with over 30 years of clinical expertise, and a commercial team with 20+ years of implant/intervention sales experience, creating a uniquely synergistic “industry-clinic-commercial” model.

Huikai’s flagship product, UroStent® — a novel urethral stent system — is the world’s first solution enabling out patient BPH (benign prostatic hyperplasia) treatment in just 5–10 minutes without general anesthesia or cystoscopy. The device has been approved by China’s National Medical Products Administration(NMPA), revolutionizing clinical treatment pathways for BPH patients.

Under this partnership, RWA Group will design blockchain-based tokenization models for Huikai’s traceable medical assets,enabling innovative financing methods such as lease-to-own models, revenue rights transfer, and socially impactful healthcare equipment programs. Initial pilots will target Southeast Asia and Middle Eastern markets, incorporating end-to-end lifecycle tracking from production to deployment, usage, and retirement.

“Huikai’s technological leadership in medical devices combined with RWA Group’s blockchain expertise will set a new benchmark for tokenized healthcare asset financing,” said an RWA Group spokes person. “This partnership bridges medical innovation with decentralized finance to unlock new capital pathways for healthcare.”

The parties are jointly working on asset verification, on-chain protocol design,compliance alignment, and cross-border payment solutions, aiming to launch the first medical device RWA token pilot in Q4 2025.

RWA Group (formerly NFT China) is a leading one-stop real-world asset (RWA) service provider in Hong Kong's Web 3.0 industry, with a focus on integrating digital financial consulting and infrastructure services. It was founded by a professional team with deep expertise in blockchain technology, finance, and digital asset infrastructure.The company is headquartered in Hong Kong Science Park. RWA Group's business network has extended deeply across Hong Kong, Mainland China, and Southeast Asia.

As the builder of world's first non-financial RWA tokenization and trading platform, RWA Group has successfully integrated RWA issuance, trading, and supporting consulting services, establishing its core competitiveness through a unique closed -loop service system of "technology implementation - regulatory compliance - ecosystem expansion." RWA Group has been consistently profitable since 2023, bringing in 50 million RMB in revenue over the past two years. The company has successfully assisted several supply chain financial assets in completing tokenization projects, such as launching the first NFT airdrop for BYD in 2021, reaching in-depth cooperation on RWA project with Faraday Future in 2025. Additionally, RWA Group won second prize in the 2024 China Web 3.0 Innovation Competition and has actively led the formulation of industry technical standards and evaluation norms, promoting the standardization of the ecosystem.

In the future, the company will continue to serve as a bridge for the globalization of non-financial assets, driving forward the global collaboration and standardization of RWA digitization, andleading a new wave of digital transformation for tangible assets.